NTIDs with high variability [Design Issues]
Which is the most appropriate design for a narrow therapeutic index drug with very high intra-subject variability?
For example, we have an immunosuppressive agent with an intra-subject CV% > 45%.
Using a standard two – way crossover design with acceptance interval tightened (90.00 – 111.11%), we will have a sample size of more than 300 subjects
.
It is possible to use a replicate design in this situation?
Thank you,
Jo
For example, we have an immunosuppressive agent with an intra-subject CV% > 45%.
Using a standard two – way crossover design with acceptance interval tightened (90.00 – 111.11%), we will have a sample size of more than 300 subjects

It is possible to use a replicate design in this situation?
Thank you,
Jo
Complete thread:
- NTIDs with high variabilityioanam 2010-06-07 13:52 [Design Issues]
- NTIDs # HVDs (or not?) Helmut 2010-06-07 14:18
- NTIDs # HVDs (or not?) ioanam 2010-06-07 18:17
- Complicated ElMaestro 2010-06-07 18:28
- NTIDs # HVDs (or not?) Dr_Dan 2010-06-08 12:24
- Switch over Helmut 2010-06-08 12:34
- NTIDs # HVDs (or not?) Relaxation 2010-06-09 22:38
- FDA scaling for NTIDs krishna 2013-01-07 14:01
- FDA scaling for NTIDs Helmut 2013-01-12 20:06
- FDA scaling for NTIDs krishna 2013-01-18 10:04
- FDA scaling for NTIDs Helmut 2013-01-20 12:46
- FDA scaling for NTIDs krishna 2013-02-01 12:20
- FDA scaling for NTIDs Helmut 2013-01-20 12:46
- FDA scaling for NTIDs krishna 2013-01-18 10:04
- FDA scaling for NTIDs Helmut 2013-01-12 20:06
- FDA scaling for NTIDs krishna 2013-01-07 14:01
- NTIDs # HVDs (or not?) Relaxation 2010-06-09 22:38
- Switch over Helmut 2010-06-08 12:34
- NTIDs # HVDs (or not?) ioanam 2010-06-07 18:17
- NTIDs # HVDs (or not?) Helmut 2010-06-07 14:18